BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

NOVOCURE — Lobbying — Receipts Report

LD-2 disclosure · 2nd Quarter - Report

NOVOCURE

via MAYER BROWN LLP

2nd Quarter (Apr 1 - June 30) · 2026Posted Jul 20, 2026Filing document ↗LDA record ↗

Income$20Kfee reported

Client

Name: NOVOCURE
Description: Medical technology company.
Location: Pennsylvania · United States of America

Registrant

Firm: MAYER BROWN LLP
Description: Law firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Trade (domestic/foreign)
Issues related to Section 232 investigations.
LobbyistsWARREN PAYNE · DANIEL HARDER
TargetedSENATE · HOUSE OF REPRESENTATIVES · U.S. Trade Representative (USTR) · Food & Drug Administration (FDA)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.